Motesanib and advanced NSCLC: experiences and expectations. - Wikidata - awgldk - TriplyDB

Motesanib and advanced NSCLC: experiences and expectations.

Motesanib and advanced NSCLC: experiences and expectations.

http://www.wikidata.org/entity/Q37870920

about

Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors Antiangiogenic effects of topically administered multiple kinase inhibitor, motesanib (AMG 706), on experimental choroidal neovascularization in mice.Thyroid dysfunctions induced by tyrosine kinase inhibitors.

P2860

Q27693185-5647D22F-8956-44B6-8049-6647E3C981C0 Q34862792-D5C2EBBD-E724-492F-9967-867C14E64E0C Q38211342-3B357234-5CEB-4EEE-ABB6-7AAA2CDED9C2

P2860

Motesanib and advanced NSCLC: experiences and expectations.

http://www.wikidata.org/entity/Q37870920

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 May 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Motesanib and advanced NSCLC: experiences and expectations.

@en

Motesanib and advanced NSCLC: experiences and expectations.

@nl

type

label

Motesanib and advanced NSCLC: experiences and expectations.

@en

Motesanib and advanced NSCLC: experiences and expectations.

@nl

prefLabel

Motesanib and advanced NSCLC: experiences and expectations.

@en

Motesanib and advanced NSCLC: experiences and expectations.

@nl

P1433

Q37870920-F19D063F-33E9-405A-B69B-5DD43437C7DE

P1476

Q37870920-96527D18-8FD8-4F22-8DC0-564B6FD9E5E9

P2093

Q37870920-27FF317B-811A-4B63-AEF4-6284B8C066EA

P2860

Q37870920-05060CBA-5027-4D0D-8007-CB3AED4B7ACC

Q37870920-0538C0D2-62E6-4DBF-90BA-BE4D1810F6BC

Q37870920-07EC2FB9-7C36-42EF-A20A-450F12B1D1AF

Q37870920-0D289179-4765-43DA-B316-E41A3581F6D7

Q37870920-0D62029B-810E-403F-A0ED-CB9437D35EA5

Q37870920-21401EFA-F09F-4147-9CF9-A981A5644807

Q37870920-317310EE-93C6-4AFD-98E0-4766982CE204

Q37870920-45B92CC7-C404-4EAF-90CA-B3F3A315BE1C

Q37870920-49E61B49-73EB-4CB1-8E84-3E54248FD79F

Q37870920-4AC7A97D-CAA0-43B0-86B1-26034F34889F

P304

Q37870920-7D87AD16-C89D-446C-9C1E-2091B6A53B90

P31

Q37870920-2D1F43F3-F382-4F50-9DE3-1DFF9FF3CC2A

P356

Q37870920-AEFE3AE7-AA2D-49AC-B404-4AAB5A81AC3C

P407

Q37870920-E00B8BA5-CDA4-4EF8-BBEC-344B3EBD6703

P433

Q37870920-978C7DBB-3196-4A74-B4E9-EA5597E2020E

P478

Q37870920-DD8AA37E-11B1-48B4-9CBD-9C5D99C0D620

P50

Q37870920-EAD5FF3B-A446-4F2E-955A-DBCE3EF6F8A3

P577

Q37870920-40EFD32E-7D53-46F3-B987-DDEF6A9DF4F5

P698

Q37870920-0410D98E-1FCE-4411-B423-B797F309599C

P356

13543784.2011.579103

P1433

Expert Opinion on Investigational Drugs

P1476

Motesanib and advanced NSCLC: experiences and expectations.

@en

P2093

Kanwal Pratap Singh Raghav

http://www.w3.org/2001/XMLSchema#string

P2860

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Erlotinib in previously treated non-small-cell lung cancer

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.

Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate

Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer.

P304

859-869

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2011.579103

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

George R Blumenschein

P577

2011-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21534718

http://www.w3.org/2001/XMLSchema#string